We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

246 hedge funds and large institutions have $6.3B invested in SALIX PHARMACEUTICALS LTD DEL in 2013 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 83 increasing their positions, 107 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more call options, than puts

Call options by funds: $83.6M | Put options by funds: $36.8M

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

57% more capital invested

Capital invested by funds: $4B → $6.3B (+$2.3B)

2% less funds holding

Funds holding: 251246 (-5)

11% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 36

22% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 107

Holders
246
Holders Change
-5
Holders Change %
-1.99%
% of All Funds
7.14%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.17%
New
32
Increased
83
Reduced
107
Closed
36
Calls
$83.6M
Puts
$36.8M
Net Calls
+$46.8M
Net Calls Change
+$6.68M
Name Holding Trade Value Shares
Change
Change in
Stake
NCGI
76
Next Century Growth Investors
Minnesota
$9.87M -$374K -4,692 -4%
State Board of Administration of Florida Retirement System
77
State Board of Administration of Florida Retirement System
Florida
$9.6M -$268K -3,355 -3%
SI
78
Scout Investments
Missouri
$9.12M -$289K -3,625 -3%
TI
79
Turner Investments
Pennsylvania
$9.08M -$2.81M -35,176 -26%
RHJA
80
Rice Hall James & Associates
California
$9.03M +$1.83M +22,961 +30%
TAM
81
Telemark Asset Management
Massachusetts
$8.99M +$1.6M +20,000 +25%
RhumbLine Advisers
82
RhumbLine Advisers
Massachusetts
$8.86M -$608K -7,619 -7%
CS
83
Credit Suisse
Switzerland
$8.81M +$1.84M +23,129 +31%
SCA
84
SAC Capital Advisors
Connecticut
$8.8M -$10.6M -132,518 -58%
CCP
85
Clough Capital Partners
Massachusetts
$8.41M -$7.4M -92,800 -50%
Morgan Stanley
86
Morgan Stanley
New York
$8.23M +$2.06M +25,819 +39%
RCAMU
87
Rothschild & Co Asset Management US
Connecticut
$8.1M +$130K +1,625 +2%
Zurich Cantonal Bank
88
Zurich Cantonal Bank
Switzerland
$7.54M -$8.19M -102,640 -55%
KCM
89
Kingdon Capital Management
New York
$7.23M -$1.46M -18,300 -19%
TAM
90
Tocqueville Asset Management
New York
$7.05M +$682K +8,549 +12%
NTCOC
91
Northern Trust Company of Connecticut
Connecticut
$6.83M +$1.79M +22,383 +42%
Retirement Systems of Alabama
92
Retirement Systems of Alabama
Alabama
$6.82M
Comerica Bank
93
Comerica Bank
Texas
$6.77M -$287K -3,595 -5%
OAM
94
Oxford Asset Management
United Kingdom
$6.75M +$3.86M +48,371 +181%
ProShare Advisors
95
ProShare Advisors
Maryland
$6.71M +$3.66M +45,833 +159%
1CM
96
1492 Capital Management
Wisconsin
$6.45M +$5.72M +71,696 New
CM
97
Castleark Management
Illinois
$6.28M +$5.1M +63,958 +1,100%
Two Sigma Investments
98
Two Sigma Investments
New York
$6.17M +$5.47M +68,642 New
TPSF
99
Texas Permanent School Fund
Texas
$5.95M +$69.6K +873 +1%
MOACM
100
Mutual of America Capital Management
New York
$5.4M -$1.34M -16,741 -22%

SLXP Hedge Fund Activity: Q4 2013 in Review

246 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q4 2013, worth a combined $6.3B — up 57% from $4B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of SLXP and 32 opened new positions — a net loss of 4 holders — while 107 trimmed existing stakes and 83 added.

The largest buyer was Fidelity Investments, adding an estimated $453M. The largest seller was Bank of America, cutting an estimated $135M.

  • 246 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q4 2013, down from 251 in Q3 2013.
  • Funds reported $6.3B of SALIX PHARMACEUTICALS LTD DEL stock for Q4 2013, up 57% quarter-over-quarter.
  • 32 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q4 2013 and 36 closed out, a net change of -4 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q4 2013 was Fidelity Investments, an estimated $453M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q4 2013 was Bank of America, an estimated $135M sold.

Based on aggregated 13F filings for Q4 2013.